Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trial

Illingworth, D. Roger; Olsen, George D.; Cook, Suzanne F.; Sexton, Gary; Wendel, Herbert; Connor, William E.

doi:10.1016/0021-9150(82)90115-0

Cited by 33 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the 30 trials with niacin, the distribution is as follows: 11 trials with immediate-release niacin (IR-niacin) (54,64 -73), 10 trials with acipimox (72,74 -82), 6 trials with extended-release niacin (ER-niacin) (67,(83)(84)(85)(86)(87), and 5 trials with wax-matrix sustained-release niacin (SR-niacin) (64,88 -91). From the 83 trials, 6 trials (21,22,54,64,67,72) used multiple treatment arms with more than one fibric acid or nicotinic acid derivative, and 15 trials had different study populations (26,28,31,33,38,44,49,51,53,58,62,68,74,75,81). Overall, in these studies 16,802 subjects were treated with fibrates or placebo, and 4,749 subjects were treated with niacin or placebo.…”

Section: Resultsmentioning

confidence: 97%

“…A total of 83 trials (53 trials for fibrates and 30 trials for niacin) met our criteria and were included in the meta-analysis (Tables 1 and 2). The distribution of the 53 trials with fibrates is as follows: 17 trials with gemfibrozil (5,6,(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), 15 trials with fenofibrate (22,28 -41), 13 trials with bezafibrate (22,(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53), 9 trials with clofibrate (21,54 -61), and 2 trials with ciprofibrate (62,63). For the 30 trials with niacin, the distribution is as follows: 11 trials with immediate-release niacin (IR-niacin) (54,64 -73), 10 trials with acipimox (72,74 -82), 6 trials with extended-release niacin (ER-niacin) (67,(83)(84)(85)(86)(87), and 5 trials with wax-matrix sustained-release niacin (SR-niacin) (64,88 -91).…”

Section: Resultsmentioning

confidence: 99%

“…Twelve trials used random assignment with a crossover design (19,21,26,27,38,40,42,45,51,57,58,61). Subjects with the following dyslipidemias and study populations were enrolled into the 83 trials: 29 trials with hypercholesterolemia (5,(22)(23)(24)(25)28,33,34,36,43,49,52,53,(55)(56)(57)59,60,62,64,67,(85)(86)(87)(88)(89)(90)92); 25 trials with type II diabetes mellitus (15,17,18,20,29,31,32,37-39,41,43,44,46,50,57,65,68,76 -79,81-83); 16 trials with combined hyperlipidemia (21,27,28,33,38,44,49,…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

Birjmohun¹,

Hutten

Kastelein³

et al. 2005

Journal of the American College of Cardiology

397

249

View full text Add to dashboard Cite

Fibrates reduce major coronary events and increase HDL-C levels without significant toxicity. Niacin has a more potent effect on HDL-C levels, whereas data on cardiovascular event rate reduction are limited. Future studies need to evaluate whether additional HDL increase by fibrates or particularly newer niacin formulations on top of statin therapy translates into further event reduction in high-risk subjects, without significant toxicity.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

Birjmohun¹,

Hutten

Kastelein³

et al. 2005

Journal of the American College of Cardiology

397

249

View full text Add to dashboard Cite

show abstract

“…Nevertheless, a marked hypergastrinemia was also recorded after ciprofibrate treatment in female Wistar rats, demonstrating that an effect of ciprofibrate on gastrin release is a general phenomenon not restricted to a particular strain of rat. The fibrates have been used clinically to reduce blood lipids (Illingworth et al 1982). Therefore, two other drugs with a lipid-reducing effect (lovastatin and simvastatin) (Singer et al 1988), acting via a different mechanism were studied.…”

Section: Discussionmentioning

confidence: 99%

The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell

Im¹,

Sylte²,

Schulze³

et al. 1998

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

The peroxisome proliferator ciprofibrate induces hypergastrinemia without inhibiting acid secretion. The present study was carried out to assess the effect of ciprofibrate on serum gastrin and gastrin (G) cells in different strains of rats and to compare the effect of ciprofibrate with other lipid-reducing agents (lovastatin and simvastatin) which have a different mechanism of action.Serum gastrin was determined by a radioimmunoassay method, G cell density by histomorphometry after immunostaining for G cells, and gastrin, somatostatin and histidine decarboxylase (HDC) mRNA abundance by Northern blot analysis.Ciprofibrate (100 mg/kg/day for three weeks) induced a marked hypergastrinemia (P<0·01) in male and female Fischer rats as well as in female Wistar rats. Simvastatin and lovastatin did not affect serum gastrin. Antral G cell density increased significantly in female Wistar rats (P<0·05) and non-significantly in the other rats after ciprofibrate. Both gastrin and somatostatin mRNA abundance in antral mucosa increased markedly and significantly (P<0·01) after ciprofibrate treatment.The present study shows that the peroxisome proliferator ciprofibrate induces hypergastrinemia secondary to an increased storage and synthesis of antral gastrin. Since somatostatin mRNA abundance also increased, the present study suggests that ciprofibrate and possibly other peroxisome proliferators in sufficient concentrations have a stimulatory effect on endocrine cells.

show abstract

“…Table 4. Effects of short-term and long-term treatment with ciprofibrdte on body wcights, serum lipids and biliary lipids in 10 hyperlipidaernic patients (Mean f SEM). patients (Fig.…”

Section: Long-term Treatmentmentioning

confidence: 99%

Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia

Angelin

Einarsson

Leijd

1984

Eur J Clin Investigation

View full text Add to dashboard Cite

Treatment with hypolipidaemic drugs such as clofibrate increases secretion of biliary cholesterol and induces supersaturation of bile, leading to an increased risk of gallstone formation. Ciprofibrate is a phenoxyisobutyrate derivative with lipid-lowering effects in hyperlipoproteinaemia. We analysed serum lipid levels and biliary lipid composition and cholesterol saturation of gallbladder bile in nineteen hyperlipoproteinaemic patients before and after 6 weeks treatment with ciprofibrate, 100 mg daily. In addition, hepatic secretion rates of biliary lipids were determined in eight of the patients. Ten of the patients were also studied after 1 year of treatment. Short-term treatment reduced the serum cholesterol levels by about 20% (P less than 0.001) and the serum triglycerides by about 40% (P less than 0.001). The relative cholesterol concentration and cholesterol saturation of bile were not significantly increased for the group as a whole, nor in patients with familial hypercholesterolaemia (n = 9), or with other types of hyperlipidaemia (n = 10). During treatment, however, fourteen patients had saturated bile compared with nine before treatment. An increase in cholesterol saturation was the consequence of an increased hepatic secretion of cholesterol whereas the secretion rates of bile acids and phospholipids were unaffected. After 1 year of treatment the serum lipid concentrations were reduced to about the same level as after 6 weeks, whereas biliary lipid composition and cholesterol saturation had returned to pre-treatment values. In contrast to clofibrate ciprofibrate exerts hypolipidaemic effects without consistently increasing the relative cholesterol concentration in bile. In some patients it leads to a transient rise in cholesterol saturation of gallbladder bile.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trial

Cited by 33 publications

References 30 publications

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell

Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia

Contact Info

Product

Resources

About